Finzati - Logo
BMRN logo

BioMarin Pharmaceutical Inc.

BMRN • Biotechnology
$66.53
▲ +0.10 (+0.15%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHLY FAVORABLE PROFILEExcellentConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$13.01B
Growth
23.7%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 10.8%Positive revenue growth · 13.6%Positive free cash flow · 3.78Consistent free cash flow · 5/5Manageable debt level · 0.11
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$66.53
Change0.15%
Shares Out194.15M
Market Cap$13.01B
Enterprise Value$16.32B
52W Range49.26 - 66.28
Beta0.23
P/E178.26
P/S3.82
P/B2.06
P/FCF13.95
EV/Sales4.79

Investment DNA

How strong this company looks for long-term investors

84
out of 100
Business Quality
Margins, moat, returns
76/100
Financial Strength
Debt, cash, stability
95/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
65/100
Why this score▼
Stable or improving margins · 10.8%Positive revenue growth · 13.6%Positive free cash flow · 3.78Consistent free cash flow · 5/5Manageable debt level · 0.11Healthy liquidity · 5.21

Analyst view

Analyst sentiment and price target

BMRN
Analyst sentiment
Based on 41 analyst votes · 2026-09-04
85/100
Bullish
Bullish
29
Hold
12
Bearish
0
Price Target
2026-08-07
Low
$50.00
Mean
$87.79
Median
$89.50
High
$120.00

Company Overview

IPO: 7/26/1999
Industry: Biotechnology
P/B i: 2.06
Debt / Equity i: 0.11
Operating Margin: 16.56%
Net Margin: 10.83%
ROE i: -
ROIC: -

Financial Health

Score19 / 20
Debt / Equity: 0.11
Current Ratio: 5.21
Quick Ratio: 3.50
Status: Strong

Insider Transactions

Recent executive and insider activity

ANDERSON ELIZABETH M
Transaction: 06/02/2026
BUY
Change
+7,490
Price
Not reported
Filing
06/04/2026
Type
BUY
Bodem Barbara W.
Transaction: 06/02/2026
BUY
Change
+7,490
Price
Not reported
Filing
06/04/2026
Type
BUY
CLARK IAN T
Transaction: 06/02/2026
BUY
Change
+7,490
Price
Not reported
Filing
06/04/2026
Type
BUY